[144] Ginkgo Bioworks Holdings, Inc. SEC Filing

Rhea-AI Filing Summary

DNA filed a Form 144 notice for a proposed sale of 5,609 Class A shares through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of 84,135. The approximate sale date listed is 10/21/2025.

The shares were acquired via restricted stock vesting as compensation on multiple dates in 2024, including 4,062 shares on 05/01/2024 and smaller vestings thereafter, totaling the amount to be sold. The filing lists 47,089,598 shares outstanding for the class. The section on recent activity shows a prior sale of 310 shares on 08/22/2025 for gross proceeds of 3,842.79.

Insights

Equity capital markets analyst

Administrative insider sale notice for 5,609 shares; neutral impact.

This Form 144 lists a proposed sale of 5,609 Class A shares on the NYSE via Fidelity, tied to restricted stock vesting compensation across several 2024 dates. Such notices are procedural disclosures for planned sales under Rule 144.

The filing also cites 47,089,598 shares outstanding for the class and one prior sale of 310 shares with gross proceeds of 3,842.79. Actual market impact depends on execution details and liquidity; the document does not specify timing beyond the approximate date.

Subsequent filings may provide execution outcomes or confirm actual share amounts sold, if any, under this notice.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	5609	84135.00	47089598	10/21/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A	05/01/2024	Restricted Stock Vesting	Issuer			4062	05/01/2024	Compensation
Class A	06/01/2024	Restricted Stock Vesting	Issuer			408	06/01/2024	Compensation
Class A	07/01/2024	Restricted Stock Vesting	Issuer			406	07/01/2024	Compensation
Class A	08/01/2024	Restricted Stock Vesting	Issuer			306	08/01/2024	Compensation
Class A	09/11/2024	Restricted Stock Vesting	Issuer			427	09/11/2024	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Steve Coen 27 Drydock Avenue 8th Floor Boston MA 02210	Class A	08/22/2025	310	3842.79

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many shares are covered by the DNA Form 144 notice?

The notice covers a proposed sale of 5,609 Class A shares.

What is the aggregate market value of the proposed sale for DNA?

The filing lists an aggregate market value of 84,135 for the shares to be sold.

When is the approximate sale date in the DNA Form 144?

The approximate sale date is 10/21/2025.

Which broker is listed for the DNA Form 144 sale?

The broker is Fidelity Brokerage Services LLC, Smithfield, RI.

How were the DNA shares to be sold acquired?

They were acquired via restricted stock vesting as compensation on several dates in 2024.

How many Class A shares are outstanding per the DNA filing?

The filing lists 47,089,598 Class A shares outstanding.

Were there any recent sales disclosed related to DNA?

Yes. A sale of 310 Class A shares on 08/22/2025 with gross proceeds of 3,842.79 is disclosed.